中医药学报2024，Vol.52Issue(6)：38-43,6.DOI:10.19664/j.cnki.1002-2392.240113
类叶牡丹3种皂苷元对L929细胞炎症模型中HDAC表达的影响
Effects of Three Sapogenins from Cauorlhyllum Robustum Maxim on HDAC Expression in L929 Cell Inflammation Model
摘要
Abstract
Objective:To investigate the inhibitory effects of three sapogenins from Cauorlhyllum Robustum Maxim on HDAC3/8 and their anti-rheumatoid arthritis(RA)activity.Methods:A TNF-α-induced inflammation model in L929 fibroblast cells was established in mice.The optimal drug concentration of the screened components and the optimal modeling concentration of TNF-α were determined using the CCK-8 method.The inflammation model was verified by ELISA using IL-6 concentration as an indicator,and the anti-inflammatory ability of the screened components was evaluated.Changes in HDAC3 and HDAC8 protein expression in L929 cells were detected using Western blot.Results:The optimal concentration of TNF-α was determined to be 10 ng/mL by the CCK-8 method.Hederagenin was used at concentrations of 500 μmol/L and 250 μmol/L,oleanolic acid at concentrations of 50 μmol/L and 25 μmol/L,and Echinocystic acid at concentrations of 25 μmol/L and 12.5 μmol/L.The IL-6 content in the L929 cell model group induced by TNF-α was significantly increased(P<0.01),and the different concentrations of drug groups showed different inhibitory effects on IL-6(P<0.05,P<0.01).The three sapogenins components significantly reduced the protein expression levels of HDAC3 and HDAC8 in the TNF-α-induced L929 cell inflammation model(P<0.05,P<0.01).Conclusion:In the TNF-α-induced L929 cell inflammation model,the three sapogenins from Cauorlhyllum Robustum Maxim showed good anti-inflammatory effects by reducing HDAC overexpression.关键词
常春藤皂苷元/刺囊酸/齐墩果酸/抗炎/类叶牡丹/组蛋白去乙酰化酶Key words
Hederagenin/Echinocystic acid/Oleanolic acid/Anti-inflammatory/Cauorlhyllum Robustum Maxim/Histone deacetylase分类
医药卫生引用本文复制引用
吕邵娃,任雨涵,祝明涛,赵诗雨,王秋红,匡海学..类叶牡丹3种皂苷元对L929细胞炎症模型中HDAC表达的影响[J].中医药学报,2024,52(6):38-43,6.基金项目
国家自然科学基金项目(81373929) （81373929）
黑龙江省"头雁"团队支持项目(黑龙江省头雁行动领导小组文件[2019]5号) （黑龙江省头雁行动领导小组文件[2019]5号）
校基金新药临床前研究基金项目(2018xy04) （2018xy04）
